Effect of Remifentanil on Propofol use administered by PCSA for procedures of diagnosis and surgery by endoscopy. - ND

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001683-23-IT

Enrollment

Registered

2006-05-25

Start date

2006-04-27

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient to underwent operation for surgery or diagnosis endoscopy of the upper gastrointestinal tract MedDRA version: 6.1 Level: PT Classification code 10014819

Interventions

Trade Name: PROPOFOL IBI 20MG/ML 1FL50ML Pharmaceutical Form: Emulsion for infusion INN or Proposed INN: Propofol CAS Number: 2078-54-8 Concentration unit: mg milligram(s) Concentration type: equal Co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with age over 18 who have to be submitted to operation for surgery or for diagnosis es endoscopy of the upper gastroenteric tract Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Main Objective: to verify if Remifentanil and Propofol togheter may guarantee an adequate anlgesic covering and may allow to reduce the quantity of hypnotic drug;Secondary Objective: -;Primary end point(s): -	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026